Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.

Literature DB >> 25109594

Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.

H Solomon¹, M Sharon², V Rotter¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2014 PMID： 25109594 PMCID： PMC4131187 DOI： 10.1038/cdd.2014.99

Source DB: PubMed Journal: Cell Death Differ ISSN： 1350-9047 Impact factor: 15.828

× No keyword cloud information.

20 in total

1. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.

Authors: Stéphanie Courtois; Gerald Verhaegh; Sophie North; Maria-Gloria Luciani; Patrice Lassus; Ula Hibner; Moshe Oren; Pierre Hainaut
Journal: Oncogene Date: 2002-10-03 Impact factor: 9.867

Review 2. Alternative splicing: new insights from global analyses.

Authors: Benjamin J Blencowe
Journal: Cell Date: 2006-07-14 Impact factor: 41.582

3. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.

Authors: D Wolf; N Harris; N Goldfinger; V Rotter
Journal: Mol Cell Biol Date: 1985-01 Impact factor: 4.272

4. Immunologically distinct p53 molecules generated by alternative splicing.

Authors: N Arai; D Nomura; K Yokota; D Wolf; E Brill; O Shohat; V Rotter
Journal: Mol Cell Biol Date: 1986-09 Impact factor: 4.272

5. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.

Authors: Kelly A Avery-Kiejda; Brianna Morten; Michelle W Wong-Brown; Andrea Mathe; Rodney J Scott
Journal: Carcinogenesis Date: 2013-12-11 Impact factor: 4.944

6. p53 isoforms can regulate p53 transcriptional activity.

Authors: Jean-Christophe Bourdon; Kenneth Fernandes; Fiona Murray-Zmijewski; Geng Liu; Alexandra Diot; Dimitris P Xirodimas; Mark K Saville; David P Lane
Journal: Genes Dev Date: 2005-08-30 Impact factor: 11.361

7. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form.

Authors: R Wolkowicz; A Peled; N B Elkind; V Rotter
Journal: Proc Natl Acad Sci U S A Date: 1995-07-18 Impact factor: 11.205

Review 8. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.

Authors: I Goldstein; V Marcel; M Olivier; M Oren; V Rotter; P Hainaut
Journal: Cancer Gene Ther Date: 2010-10-22 Impact factor: 5.987

9. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

Authors: G Hofstetter; A Berger; E Schuster; A Wolf; G Hager; I Vergote; I Cadron; J Sehouli; E I Braicu; S Mahner; P Speiser; C Marth; A G Zeimet; H Ulmer; R Zeillinger; N Concin
Journal: Br J Cancer Date: 2011-10-18 Impact factor: 7.640

Review 10. Aberrant alternative splicing is another hallmark of cancer.

Authors: Michael Ladomery
Journal: Int J Cell Biol Date: 2013-09-11

16 in total

Review 1. Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

Authors: Diego M Marzese; Ayla O Manughian-Peter; Javier I J Orozco; Dave S B Hoon
Journal: Clin Exp Metastasis Date: 2018-05-29 Impact factor: 5.150

2. Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation.

Authors: Xue Gong; Miao Tian; Nian Cao; Peili Yang; Zaicheng Xu; Shuo Zheng; Qiao Liao; Caiyu Chen; Cindy Zeng; Pedro A Jose; Da-Zhi Wang; Zhao Jian; Yingbin Xiao; Ding-Sheng Jiang; Xiang Wei; Bing Zhang; Yibin Wang; Ken Chen; Gengze Wu; Chunyu Zeng
Journal: J Clin Invest Date: 2021-12-15 Impact factor: 14.808

Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.

1. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.

Review 2. Alternative splicing: new insights from global analyses.

3. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.

4. Immunologically distinct p53 molecules generated by alternative splicing.

5. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.

6. p53 isoforms can regulate p53 transcriptional activity.

7. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form.

Review 8. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.

9. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

Review 10. Aberrant alternative splicing is another hallmark of cancer.

Review 1. Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

2. Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation.

Review 3. p53 Isoforms: Key Regulators of the Cell Fate Decision.

4. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain.

5. TAp73 upregulates IL-1β in cancer cells: Potential biomarker in lung and breast cancer?

6. Identification of nonsense-mediated mRNA decay pathway as a critical regulator of p53 isoform β.

Review 7. P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development.

Review 8. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis.

9. p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression.

10. Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells.